Skip to content
Research articles with safety and study context in view.
Your Peptide Tracker

Logging fresh findings for semaglutide, KPV, MOTS-c.

Menu

References for the peptide research

These are the sources cited across Your Peptide Tracker. The descriptions explain each source's role rather than treating every publication as equivalent evidence. A randomized trial compares assigned groups; a cohort follows observations; a laboratory study examines an experimental system. Agency material addresses regulatory status or a safety assessment.

Reading the source list

Hands separating printed research pages across a broad oak desk.

The linked records identify the publications and official documents. Study results belong with their population, methods, follow-up, and limitations. A paper's abstract is useful for orientation, while the full publication may be needed to assess exclusions, adverse events, or how a statistical estimate was calculated. DOI strings below identify individual papers.

Semaglutide studies and prescribing information

Wilding and colleagues, 2021

This STEP 1 publication reports weight outcomes in adults with obesity or overweight and a related condition, without diabetes. It is the source for the 68-week comparison discussed on the semaglutide page. Open the trial record. DOI: 10.1056/NEJMoa2032183.

Lincoff and colleagues, 2023

The SELECT investigators examined cardiovascular events in people with established disease and excess weight, without diabetes. Their trial supports the event comparison here, including the distinction between an absolute difference and a relative reduction. Open the SELECT record. DOI: 10.1056/NEJMoa2307563.

Perkovic and colleagues, 2024

FLOW studied adults who had both type 2 diabetes and chronic kidney disease. Its combined kidney-related outcome is discussed separately from weight trials because it addresses different participants and a different clinical question. Open the FLOW record. DOI: 10.1056/NEJMoa2403347.

Smits and Van Raalte, 2021

This safety review brings together semaglutide evidence, including digestive adverse effects and other cautions. It supplies context rather than a new randomized participant group. Current product information remains important when reading a review from an earlier year. Open the review record. DOI: 10.3389/fendo.2021.645563.

Wegovy prescribing information, 2026

The National Library of Medicine's DailyMed record carries the product's prescribing information, including approved uses and safety warnings. The version recorded here was updated June 18, 2026. It concerns specified manufactured products, rather than every preparation of semaglutide. Read the prescribing information.

Retatrutide trial publications

Jastreboff and colleagues, 2023

This randomized phase 2 obesity trial followed 338 adults for 48 weeks. It provides the earlier weight results and the reported pattern of heart-rate increases, alongside digestive adverse effects. Later publications add evidence without changing this study's design. Open the phase 2 record. DOI: 10.1056/NEJMoa2301972.

Jastreboff and colleagues, 2026

TRIUMPH-1 reports an 80-week phase 3 trial in adults without diabetes, funded by Lilly. The site uses its treatment-regimen analysis, which accounts for treatment changes, rather than combining estimates based on different assumptions. Open the TRIUMPH-1 record. DOI: 10.1056/NEJMoa2604169.

Bellido and colleagues, 2026

TRIUMPH-2 studied adults with type 2 diabetes and excess weight over 80 weeks, also with Lilly funding. Its population and adverse-effect reporting are relevant when interpreting the weight findings beside the non-diabetes trial. Open the TRIUMPH-2 record. DOI: 10.1016/S0140-6736(26)01861-1.

MOTS-c experiments and observations

Reynolds and colleagues, 2021

This publication includes exercise-related peptide measurements and mouse experiments administering MOTS-c. The article here uses it for the animal performance findings, while keeping those findings apart from claims about human endurance or aging treatment. Open the exercise-study record. DOI: 10.1038/s41467-020-20790-0.

Kim and colleagues, 2018

These laboratory experiments examined movement of MOTS-c into the cell nucleus during metabolic stress and associated gene responses. They contribute mechanistic evidence, without supplying a clinical outcome in treated people. Open the cell-study record. DOI: 10.1016/j.cmet.2018.06.008.

Kumagai and colleagues, 2024

Direct-binding tests and mouse experiments identified CK2 as a molecular target relevant to muscle research. This work helps explain an experimental pathway; it does not establish a patient benefit or a human treatment regimen. Open the muscle-study record. DOI: 10.1016/j.isci.2024.111212.

Bolignano and colleagues, 2024

This observational cohort measured natural MOTS-c in 94 people receiving chronic hemodialysis. Its association with later events informs the discussion of biomarkers. Participants were observed rather than assigned MOTS-c treatment. Open the cohort record. DOI: 10.1159/000540303.

ClinicalTrials.gov MOTS-MET record, 2026

The registration describes an intervention study in adults with prediabetes and excess weight. A protocol and enrollment plan are distinct from completed findings; the record used here contains no results. Read registration NCT07505745.

KPV laboratory and animal studies

Dalmasso and colleagues, 2008

This paper combines cultured intestinal and immune cells with mouse colitis experiments. It supports discussion of PepT1 uptake and inflammatory signaling, with the experimental setting retained. Human cells in culture are not a treated patient population. Open the uptake-study record. DOI: 10.1053/j.gastro.2007.10.026.

Kannengiesser and colleagues, 2008

Mouse models of bowel inflammation supplied the recovery and weight-regain findings discussed here. Their meaning depends on the animals' illness and the induced experimental condition, rather than on weight change considered alone. Open the recovery-study record. DOI: 10.1002/ibd.20334.

Xiao and colleagues, 2017

The investigators tested targeted KPV carriers in mice with colitis. The delivery system is central to interpreting the outcome, so the site's discussion does not extend it to every KPV formulation. Open the delivery-study record. DOI: 10.1016/j.ymthe.2016.11.020.

Pawar and colleagues, 2017

Donated human skin samples were used to investigate passage of KPV under laboratory conditions. The experiments address a barrier to delivery, rather than treatment effectiveness in living participants. Open the skin-study record. DOI: 10.1016/j.xphs.2017.03.017.

Official safety and policy documents

FDA's 2026 advisory-meeting briefings describe missing safety information and the evidence reviewed for KPV and MOTS-c. These are agency assessments, separate from the later HHS draft. The FDA substance-status page distinguishes nominated but withdrawn substances from the current Category 2 table.

FDA's unapproved GLP-1 product discussion addresses product and ingredient concerns, including retatrutide's nonapproval. In the draft policy published October 30, 2026, 91 FR 68526, HHS said it does not intend to take enforcement action against state-licensed pharmacies and licensed physicians that compound KPV or MOTS-c for an individual patient's prescription under set conditions. The nonbinding draft covers single-active-ingredient preparations, excluding blends and 503B outsourcing facilities. It gives no FDA approval, and neither peptide is on FDA's 503A bulks list.

Compare the findings